Microalbuminuria as a target to improve cardiovascular and renal outcomes in diabetic patients

被引：13
作者：
Basi S. [1 ]
Lewis J.B. [1 ]
机构：
[1] Vanderbilt University Medical Center, Division of Nephrology, Nashville, TN 37232
来源：
Current Diabetes Reports | 2007年 / 7卷 / 6期
关键词：
Diabetic Nephropathy; Rosiglitazone; Amlodipine; Heparan Sulfate; Valsartan;
D O I：
10.1007/s11892-007-0074-7
中图分类号：
学科分类号：
摘要：
Microalbuminuria has been shown to be a risk factor for adverse renal and cardiovascular outcomes in patients with diabetes mellitus. This risk appears to increase with higher levels of albuminuria. There is also evidence that reducing the level of albuminuria improves these outcomes. This review focuses on the most recent advances in this area and reviews literature over the past year on this topic. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：439 / 442
页数：3
相关论文
共 26 条
[1]  
Yokoyama H., Kawai K., Kobayashi M., Microalbuminuria is common in Japanese type 2 diabetic patients, Diabetes Care, 30, pp. 989-992, (2007)
[2]  
Lewis E.J., Hunsicker L.G., Clarke W.R., Et al., Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, pp. 851-860, (2001)
[3]  
Brenner B.M., Cooper M.E., de Zeeuw D., Et al., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, pp. 861-890, (2001)
[4]  
Anavekar N.S., Gans D.J., Berl T., Et al., Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: A case for albuminuria, Kidney Int, 66, (2004)
[5]  
de Zeeuw D., Remuzzi G., Parving H.H., Et al., Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy, Circulation, 110, pp. 921-927, (2004)
[6]  
Gerstein H.C., Mann J.F.E., Yi Q., Et al., Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals, JAMA, 286, pp. 421-426, (2001)
[7]  
Araki S., Haneda M., Koya D., Et al., Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes, Diabetes, 56, pp. 1727-1730, (2007)
[8]  
Standards of medical care, Diabetes Care, 28, SUPPL. 1, (2005)
[9]  
Arnlov J., Evans J., Meigs J., Et al., Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals, the Framingham heart study, Circulation, 112, pp. 969-975, (2005)
[10]  
Comper W.D., Osicka T.M., Albumin-like material in urine, Kidney Int Suppl, 92, (2004)
123